The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

CIT Stack

CJC-1295 Ipamorelin Tesamorelin Stack · CIT Stack

C
Animal replicated
Research chemicalGH Secretagogue StackGHRH AnalogGHRPPeptide Stack
RouteInjectableGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
CJC-1295 + Ipamorelin + Tesamorelin — GH Secretagogue / Visceral-Fat Stack — GH Secretagogue Stack, GHRH Analog, GHRP, Peptide Stack.
Why people use it
Used primarily for muscle and performance and sleep and recovery.
What the evidence supports
The CIT Blend uses CJC-1295 WITHOUT DAC (also called Mod GRF 1-29) — the pulsatile form with ~30 min half-life. CJC-1295 WITH DAC (8-day half-life; sustained non-pulsatile GH elevation) is incompatible with this protocol for the same reasons documented in the GH Stack chapter: DAC blunts natural GH pulsatility, risks receptor desensitization, and is pharmacologically antithetical to the pulsatile protocol that makes CJC+Ipa synergistic. CJC-1295 DAC also does not pair meaningfully with Tesamorelin (which is pulsatile) in a coherent protocol. Always verify no-DAC.
If you only read one thing

The CIT Blend runs two GHRH analogs simultaneously — CJC-1295 (no-DAC) and Tesamorelin — plus Ipamorelin. The pharmacological question: can two GHRH analogs produce additive GHRH receptor activation, or does the first compound substantially saturate the receptor such that the second adds minimal additional GH release? GHRH receptor dynamics (occupancy, Gq coupling, downstream amplification) determine whether this is additive, synergistic, or redundant. No published study addresses this question for the specific CJC-1295 + Tesamorelin combination. Community clinical practice from the Peptide Partners context suggests value; the mechanistic basis for why two GHRH analogs would produce additive rather than saturating effects is not established. Tesamorelin may contribute through mechanisms beyond pure GHRH receptor activation — including direct adipocyte effects that CJC-1295 alone may not produce at the same magnitude. This remains an open pharmacological question.

Check interactions →
Published literature
0human trials0human studies0animal0in vitro
Evidence reality check
Human evidence
No human studies
0 observational; RCT evidence not present in corpus.
Preclinical base
0 lab signals
0 animal; 0 in-vitro/mechanistic.
Evidence snapshot
The CIT Blend uses CJC-1295 WITHOUT DAC (also called Mod GRF 1-29) — the pulsatile form with ~30 min half-life. CJC-1295 WITH DAC (8-day half-life; sustained non-pulsatile GH elevation) is incompatible with this protocol for the same reasons documented in the GH Stack chapter: DAC blunts natural GH pulsatility, risks receptor desensitization, and is pharmacologically antithetical to the pulsatile protocol that makes CJC+Ipa synergistic. CJC-1295 DAC also does not pair meaningfully with Tesamorelin (which is pulsatile) in a coherent protocol. Always verify no-DAC.
From the chapter quick-reference block.
Categories
Muscle & PerformanceSleep & RecoveryWeight Loss & Metabolic
Properties
Active malignancy: cautionWADA S2Not injectable
Half-life
The CIT Blend uses CJC-1295 WITHOUT DAC (also called Mod GRF 1-29) — the pulsatile form with ~30 min half-life
Evidence
CAnimal replicated
Stack Identity
Type: stack. Slug: cit-stack. stackGrade: B (GH Stack subset is B-grade; Tesamorelin has FDA approval and Phase 3 data; the triple combination lowers to B pending combination trial data). Components: cjc-1295-no-dac + ipamorelin + tesamorelin. Peptide Partners sells this specific CIT blend. relatedStacks: gh-stack (CJC+Ipa subset), metabolic-stack.
What CIT Stands For
CIT = CJC-1295 + Ipamorelin + Tesamorelin. Each letter represents one GH axis compound. CJC-1295 (no-DAC) and Tesamorelin are both GHRH analogs acting on the GHRH receptor. Ipamorelin is a GHRP acting on GHS-R1a. The CIT blend therefore includes two GHRH receptor agonists and one ghrelin receptor agonist, compared to the standard GH Stack which uses one GHRH analog and one GHRP.
The Three Components
CJC-1295 (no-DAC; Mod GRF 1-29): GHRH receptor agonist; ~30 min half-life; pulsatile GH stimulation. Ipamorelin: GHS-R1a agonist; selective (no cortisol/prolactin); GH pulse trigger + somatostatin suppression. Tesamorelin (EGRIFTA): FDA-approved (2010) GHRH analog for HIV-associated lipodystrophy (visceral fat); 40-AA GHRH with added trans-3-hexenoic acid; pulsatile; visceral fat reduction primary evidence; distinct from CJC-1295 in structure and regulatory status.
What Tesamorelin Adds
Tesamorelin's primary clinically validated effect is visceral adipose tissue (VAT) reduction. LIPO-010 Phase 3 trial (Falutz 2007, NEJM): -15.2% trunk fat at 26 weeks vs placebo in HIV-lipodystrophy patients. This visceral fat reduction data is the strongest of any GHRH analog. The question: does tesamorelin add visceral fat reduction benefit over CJC-1295 no-DAC when both are running simultaneously? The honest answer: no comparison study exists; two GHRH analogs may saturate the GHRH receptor without additive benefit.
The Key Uncertainty
Running CJC-1295 (no-DAC) and Tesamorelin simultaneously means two GHRH receptor agonists are competing for the same receptor. If the GHRH receptor is substantially occupied by CJC-1295, additional Tesamorelin may produce minimal incremental GH release — but does still add Tesamorelin's specific visceral fat reduction pharmacology which may involve additional mechanisms (including direct effects on adipocytes). No study has compared CJC+Ipa vs CJC+Ipa+Tesamorelin head-to-head. This is the central pharmacological question this stack chapter cannot fully answer.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
Sermorelin
C
Same class · GHRH Analog

Genuinely FDA-Approved for 18 Years. Withdrawn for Commercial Reasons, Not Safety. The Gateway Anti-Aging Peptide for a Decade of Compounding Medicine. Put on Category 2 in 2023. Apparently Returned to Category 1 Before the Broader 2026 Reclassification. The Cleanest Safety Profile of Any GH Secretagogue. The Somatostatin Feedback Ceiling That Makes It Physiologically Impossible to Overdose.

CJC-1295 (no-DAC)
C
Same class · GHRH Analog

The Most Common Community GHRH Analog — Sold Under Three Names. The DAC Confusion That Has Been Causing Purchasing Errors for a Decade. Why DAC Changes Everything About the Dosing Protocol. The Four Substitutions That Make Mod GRF 1-29 Last Long Enough to Work. How the GHRH Receptor and GHS-R1a Receptors Synergize. Why Teichman 2006 Actually Studied CJC-1295 WITH DAC — Not This Compound. The Empty Stomach Rule Is Not Optional.

CJC-1295 + Ipamorelin
C
Same class · GH Secretagogue Stack

The Most Prescribed GH Secretagogue Combination in Clinical Practice — and the One Decision That Changes Everything: DAC or No DAC.

Check interactions